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ABSTRACT
The Human Metabolome Database (HMDB) is cur-
rently the most complete and comprehensive
curated collection of human metabolite and human
metabolism data in the world. It contains records
for more than 2180 endogenous metabolites with
information gathered from thousands of books,
journal articles and electronic databases. In addition
to its comprehensive literature-derived data, the
HMDB also contains an extensive collection of
experimental metabolite concentration data com-
piled from hundreds of mass spectra (MS) and
Nuclear Magnetic resonance (NMR) metabolomic
analyses performed on urine, blood and cere-
brospinal fluid samples. This is further supple-
mented with thousands of NMR and MS spectra
collected on purified, reference metabolites. Each
metabolite entry in the HMDB contains an average
of 90 separate data fields including a comprehen-
sive compound description, names and synonyms,
structural information, physico-chemical data, ref-
erence NMR and MS spectra, biofluid concentra-
tions, disease associations, pathway information,
enzyme data, gene sequence data, SNP and muta-
tion data as well as extensive links to images,
references and other public databases. Extensive
searching, relational querying and data browsing
tools are also provided. The HMDB is designed to
address the broad needs of biochemists, clinical
chemists, physicians, medical geneticists, nutrition-
ists and members of the metabolomics community.
The HMDB is available at: www.hmdb.ca
INTRODUCTION
Metabolomics is a newly emerging ﬁeld of ‘omics’ research
concerned with the high-throughput identiﬁcation, quantiﬁca-
tion and characterization of the small molecule metabolites
in the metabolome (1). The metabolome can be deﬁned as
the complete complement of all small molecule (<1500 Da)
metabolites found in a speciﬁc cell, organ or organism. It
is a close counterpart to the genome, the transcriptome and
the proteome. Together these four ‘omes’ constitute the
building blocks of systems biology. Thanks to the Human
Genome Project most of the human genome, transcriptome
and proteome are now known and the data are electronically
available. Unfortunately, the same cannot be said of the
human metabolome. To remedy this situation, the Human
Metabolome Project (HMP) was launched in 2004 as part
of an effort to identify and quantify all detectable metabolites
(>1 mM) in the human body. In addition to experimentally
identifying and quantifying hundreds of metabolites in dif-
ferent body ﬂuids, this multi-year project was also formally
tasked with backﬁlling and validating the information on
all previously identiﬁed metabolites and providing this infor-
mation as a freely available electronic database called the
Human Metabolome Database (HMDB).
The foundation to all metabolomics research lies in the
work done by hundreds of metabolic biochemists and clinical
chemists over the past 70 years. The pathways, reactions and
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available in many excellent on-line metabolic pathway data-
bases such as KEGG (2), BioCyc (3) and Reactome (4). More
recently, information about the genes and diseases that are
associated with perturbations to these pathways has come
on-line through such outstanding resources as OMMBID
(5) and OMIM (6). However, the information contained in
these databases does not meet the unique data requirements
for metabolomics researchers, especially those involved in
human metabolomics. This is because human metabolomics
is often concerned with rapidly identifying dozens of
metabolites at a time and then using these metabolites or
combinations of metabolites as disease and/or phenotypic
biomarkers. As a result, metabolomics researchers need data-
bases that can be searched using Nuclear Magnetic Reso-
nance (NMR) spectra, mass spectra (MS), chemical
structures or chemical formulas—as opposed to sequences
or sequence names (7). Likewise metabolomics researchers
routinely need to search for metabolite concentrations, prop-
erties, locations or metabolite-disease associations. There-
fore, metabolomics databases require information not only
about compounds and reactions but also data about com-
pound concentrations, bioﬂuid or tissue locations, subcellular
locations, physical properties, known disease associations,
nomenclature, descriptions, enzyme data, mutation data and
characteristic MS or NMR spectra. These data need to be
readily available, experimentally validated, fully referenced,
easily searched, readily interpreted and they need to cover
as much of the human metabolome as possible. In other
words, metabolomics researchers need a metabolic equivalent
to GenBank or SwissProt. To address these needs, and to
serve as a potential model for other metabolomic resources,
we have developed the HMDB.
DATABASE DESCRIPTION
Fundamentally the HMDB is a multi-purpose bioinformatics–
cheminformatics–medical informatics database with a strong
focus on quantitative, analytic or molecular-scale information
about metabolites, their associated enzymes or transporters
and their disease-related properties. In many respects the
HMDB combines the data-rich molecular biology content
normally found in curated sequence databases such as Swis-
sProt and UniProt (8) with the equally rich data found in
KEGG (about metabolism) and OMMBID (about clinical
conditions). It also brings in a large body of independently
collected experimental data, including NMR spectra, MS
spectra, solubility data and validated metabolite concentra-
tions, to compliment this literature-derived data.
The diversity of data types, the quantity of experimental
data and the required breadth of domain knowledge made
the assembly of the HMDB both difﬁcult and timeconsuming.
To compile, conﬁrm and validate this comprehensive collec-
tion of data, more than two dozen textbooks, several thousand
journal articles, nearly 30 different electronic databases, and
at least 20 in-house or web-based programs were individually
searched, accessed, compared, written or run over the course
of the previous two years. In addition, more than 2100 conﬁr-
matory NMR and MS spectra were collected, 160 experi-
mental solubility determinations were made, 75 organic
syntheses were completed and hundreds of high-performance
liquid chromatography (HPLC) separations were performed.
The team of HMDB contributors and annotators included
three organic chemists, six NMR spectroscopists, ﬁve mass
spectroscopists, two separation specialists, three physicians
and 14 bioinformaticians with dual training in computing
science and molecular biology/chemistry.
The HMDB currently contains more than 2180 human
metabolite entries that are linked to more than 27700 differ-
ent synonyms. These metabolites are further connected to
some 115 non-redundant pathways, 2080 distinct enzymes,
110000 SNPs as well as 862 metabolic diseases (genetic
and acquired). More than 400 compounds are also linked to
experimentally acquired ‘reference’
1H and
13C NMR and
MS/MS spectra. Concentration data (normal and abnormal
values) for plasma, urine, CSF and/or other bioﬂuids are
also provided for a total of 883 compounds. The entire
database, including text, sequence, structure and image data
occupies nearly 18 GB of data—most of which can be freely
downloaded.
The HMDB is fully searchable with many built-in tools for
viewing, sorting and extracting metabolites, bioﬂuid concen-
trations, enzymes, genes, NMR or MS spectra and disease
information. Detailed instructions on where to locate and
how to use these browsing/search tools are provided on the
HMDB homepage. As with any web-enabled database, the
HMDB supports standard text queries (through the text search
box located near the top of each page). It also offers general
database browsing using the ‘Browse’ and ‘Bioﬂuids’ buttons
located in the HMDB menu bar. To facilitate data browsing,
the HMDB is divided into synoptic summary tables which, in
turn, are linked to more detailed ‘MetaboCards’—in analogy
to the very successful DrugCards concept found in DrugBank
(9). All of the HMDB’s summary tables can be rapidly
browsed, sorted or reformatted in a manner similar to the
way PubMed (10) abstracts may be viewed. Clicking on the
MetaboCard button found in the leftmost column of any
given HMDB summary table opens a webpage describing
the compound of interest in much greater detail. Each
MetaboCard entry contains more than 90 data ﬁelds (Table 1)
with half of the information being devoted to chemical
or physico-chemical data and the other half devoted to
biological or biomedical data (disease, bioﬂuid concentration,
enzyme, gene, SNP or metabolic pathway information). In
addition to providing comprehensive numeric, sequence and
textual data, each MetaboCard also contains hyperlinks to
many other databases (KEGG, BioCyc, PubChem, ChEBI,
PubMed, PDB, SwissProt, GenBank, OMIM and dbSNP),
abstracts, digital images and applets for viewing molecular
structures (Figure 1).
A key feature that distinguishes the HMDB from other
metabolic resources is its extensive support for higher level
database searching and selecting functions. In addition to
the data viewing and sorting features already described, the
HMDB also offers a chemical structure search utility, a
local BLAST search (11) that supports both single and
multiple sequence queries, a boolean text search based on
GLIMPSE (12), a relational data extraction tool, an MS
spectral matching tool and an NMR spectral search tool
(for identifying compounds via MS or NMR data from
other metabolomic studies).
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is the equivalent to BLAST for chemical structures. Users
may sketch [through Advanced Chemistry Development’s
(ACD) freely available ChemSketch applet] or paste a
SMILES string (13) of a query compound into the Chem-
Query window. Submitting the query launches a structure
similarity search tool that looks for common substructures
from the query compound that match the HMDB’s metabolite
database. High scoring hits are presented in a tabular format
with hyperlinks to the corresponding MetaboCards (which in
turn links to the protein target). The ChemQuery tool allows
users to quickly determine whether their compound of inter-
est is a known metabolite or chemically related to a known
metabolite. In addition to these structure similarity searches,
the ChemQuery utility also supports compound searches on
the basis of chemical formula and molecular weight ranges.
The BLAST search (SeqSearch) allows users to search
through the HMDB via sequence similarity as opposed to
chemical similarity. A given gene or protein sequence may
be searched against the HMDB’s sequence database of
metabolically important enzymes and transporters by pasting
the FASTA formatted sequence (or sequences) into the
SeqSearch query box and pressing the ‘submit’ button. A
signiﬁcant hit reveals, through the associated MetaboCard
hyperlink, the name(s) or chemical structure(s) of metabolites
that may act on that query protein. With SeqSearch
metabolite-protein interactions from recently sequenced
mammals (chimp, rat, mouse, dog, cat, etc.) may be mapped
to these organisms via the human data in the HMDB.
The HMDB’s data extraction utility (Data Extractor)
employs a simple relational database system that allows users
to select one or more data ﬁelds and to search for ranges,
occurrences or partial occurrences of words or numbers.
The Data Extractor uses clickable web forms so that users
may intuitively construct SQL-like queries. The data extrac-
tion tool allows users to easily construct complex queries as
‘ﬁnd all diseases where the concentration of homogentisic
acid in urine is >1m M ’ .
The NMR and MS search utilities allow users to upload
spectra (for the MS search) or peak lists (for the NMR search)
and to search for matching compounds from the HMDB’s
collection of MS and NMR spectra. The HMDB contains
approximately 3800 predicted 1H and
13C NMR spectra for
1900 compounds. The predicted
1H and
13C NMR spectra
were generated using the ACD/HNMR and ACD/CNMR
software from Advanced Chemistry Development Inc. Vali-
dated Mol ﬁles for each compound were used as input for
each prediction. In addition, the HMDB contains 930 experi-
mentally collected
1H and
13C NMR spectra for 400 pure
compounds (most collected in water at pH 7.0, 10 mM for
1H, 50 mM for
13C). It also contains 1200 MS/MS (Triple-
Quad) spectra at three different collision energies for nearly
400 pure compounds. An average of 50 new NMR and MS
spectra are being added each month. The HMDB’s spectral
search utilities allow both pure compounds and mixtures of
compounds to be identiﬁed from their MS or NMR spectra
via peak matching algorithms that were developed in-house.
The NMR spectral matching algorithm uses a simple peak
matching rule with pre-deﬁned chemical shift tolerances.
Query spectra are scored on the number of peak matches
to the database spectra. The MS/MS spectral matching algo-
rithm uses a peak matching and spectral scoring concept
similar to one previously published by our group (14). The
complete set of annotated spectral images (NMR and MS,
both experimental and predicted) are retrievable as zip ﬁles
through the ‘Download’ button located at the top of the
HMDB menu.
The link ‘HML Home’ in the HMDB menu bar refers to
the Human Metabolite Library. This is a repository of all pur-
chased, synthesized and isolated metabolites that have been
acquired by the HMP team. Small quantities of individual
compounds or larger collections of metabolites may be pur-
chased (at cost) or freely acquired for collaborative research
(via material transfer agreements) through the HML website
and its web ordering forms. These compounds may be used
as reference or quantitation standards by metabolomics
researchers, or the collections may be used for drug screen-
ing, crystal screening and enzyme function assays.
Perhaps the most relevant features of the HMDB from the
perspective of a medical geneticist or a clinical chemist are
its rich content and extensive linkage to metabolic diseases,
to normal and abnormal metabolite concentration ranges
(in many different bioﬂuids), to mutation/SNP data and to
the genes, enzymes, reactions and pathways associated with
many diseases of interest. Currently, the HMDB contains
115 metabolic pathway diagrams or metabolic maps. While
this number may seem small, the total number of known
human pathways in the KEGG database is just 190, with 72
of these being protein-only pathways (i.e. no metabolites).
Nevertheless, this total is expected to increase as there are
a growing number of novel gene-metabolite regulation path-
ways being identiﬁed via nutrigenomic research—many of
which will be included in the HMDB. There are also a
Table 1. Summary of the data fields or data types found in each MetaboCard
Metabolite and medical information Protein/enzyme information
Common name Enzyme/protein name
Description Enzyme/protein synonyms
Synonyms/IUPAC name Enzyme/protein sequence
Chemical structure Protein number of residues
Chemical taxonomy Protein molecular weight
Molecular weight (mono and ave) Protein pI
SMILES (isomeric and canonical) Protein gene ontology
KEGG/PubChem/OMIM/MetaGene links Protein general function
CAS number Protein specific function
InChi identifier Protein pathways
Melting point Protein reactions
Water solubility (predicted and expt) Protein Pfam domains
State (solid, liquid, gas) Protein signal sites
pKa or pI Protein transmembrane regions
LogP or hydrophobicity Protein metabolic importance
MOL/SDF/PDF text files Protein/enzyme EC link
MOL/PDB image files GenBank, SwissProt, PDB ID
NMR spectra (predicted, calculated) Protein structure data
Location (cell, biofluid, tissue) Protein cellular location
Concentration (urine, plasma, CSF) Gene sequence
Associated disorders GenBank ID
Abnormal concentration (urine, plasma,
CSF)
Chromosome location
Metabolic pathways (KEGG, SimCell) Chromosome locus
Metabolizing enzymes Protein/enzyme SNPs/mutations
Metabolizing ENZYMES Protein/enzyme references
A more complete listing is provided under the HMDB ‘Misc’ hyperlink on the
HMDB menu bar.
Nucleic Acids Research, 2007, Vol. 35, Database issue D523number of important drug and xenobiotic metabolism path-
ways (not in KEGG or Reactome) that will be added over
the coming months.
A particularly recent addition to the HMDB is a series
of SimCell (15) metabolic wiring diagrams, SimCell models
in SBML (Systems Biology Markup Language) and SimCell
simulations of nearly 30 well-characterized metabolic path-
ways. SimCell is a metabolic simulation software package
that allows complex metabolic pathways to be modeled at
a cellular level and for ‘real-time’ movies of the enzymatic
Figure 1. A screenshot montage of the Human Metabolome Database (HMDB) showing several of HMDB’s search and data display tools describing the
metabolite 1-Methylhistidine. Not all fields are shown.
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these pre-assembled metabolic models should allow users to
simply download the SimCell wiring diagram and conduct
‘in silico’ gene knock-out experiments or test hypotheses
‘in silico’ concerning the possible causes of a suspected
genetic disorder.
QUALITY ASSURANCE, COMPLETENESS AND
CURATION
The human metabolome is not as well deﬁned as the human
genome. The constitution of the metabolome depends on how
a metabolite is deﬁned, including its molecular weight cutoff,
origin and concentration limit. If every small molecule in
the body (food additive, plant extract, drug, drug derivative,
toxin, cleaning agent or environmental contaminant) were
to be included—from any source at any concentration
level—the number of compounds might exceed 100000. To
make the database both relevant and reasonable, the criteria
for inclusion in the HMDB is as follows: the compound
must weigh <1500 Da, it should be found at concentrations
greater than 1 mM (either in normal or in diseased conditions)
in one or more bioﬂuids/tissues and it should be of biological
origin (either generated by human cells or endogenous gut
microﬂora). Some exceptions are made, including low abun-
dance but biomedically important metabolites (hormones,
disease-associated metabolites, essential nutrients and signal-
ing molecules), certain very common drugs (acetaminophen,
nicotine) and some ubiquitous food additives (cellobiose,
vitamins). Separate databases are being developed by the
HMP consortium to include drugs (DrugBank), food additives
and toxins.
In annotating the HMDB, every effort is made to ensure
that the database is as complete, correct and current as possi-
ble. Metabolites are ﬁrst identiﬁed by literature surveys
(PubMed, OMIM, OMMBID, text books), data mining
(KEGG, Metlin, BioCyc) or experimental methods. If the
compound passes the HMDB inclusion criteria, information
about the metabolite is entered or prepared by one member
of the curation team and separately validated by second mem-
ber of the curation team. Additional spot checks are routinely
performed on each entry by senior members of the curation
group, including two PhD-level biochemists. The annotation
effort is also aided by several software packages including
text mining tools, chemical parameter calculators and protein
annotation tools originally developed for DrugBank (9) but
modiﬁed for the HMDB. These tools collate and display
text (and images) from multiple sources allowing the curators
to compare, assess, enter and correct metabolite or enzyme/
gene information. The source data and software tools used
in the annotation process are described in more detail under
the ‘Explain’ button located in the HMDB menu bar.
All data is entered into a centralized laboratory information
management system (LIMS) allowing all changes and edits
to the HMDB to be monitored, dated and automatically
transferred. Consistency checks (molecular weight matches
chemical formula, state consistent with melting point, no
negative molecular weights, name formatting is correct,
etc.) are performed every night using an automated checking/
correcting script. A second text tracking system has been
implemented to monitor and display up-to-date statistics on
the number of metabolites, enzymes, non-redundant
sequences and other HMDB statistics. This information is
displayed on the ‘Download’ page. Proteins that act on, trans-
port or bind to the metabolites in the HMDB are identiﬁed
and conﬁrmed using multiple sources (PubMed, KEGG, Bio-
Cyc, textbooks) as are all metabolite structures, concentra-
tions and pathways (KEGG, PubChem, journals, textbooks).
Every effort is being made to validate reported concentration
data using independent experimental methods.
DATABASE IMPLEMENTATION
The HMDB is essentially a web-friendly front-end to a
sophisticated MySQL relational database (version 4.1.7).
Both are maintained on a Linux server equipped with a
2 GHz CPU processor and 1 GB of RAM. Perl scripts are
run every night to read selected portions of the MySQL data-
base and to write out the data into GLIMPSE-indexed raw
text and XML formats The raw text is dynamically rendered
into HTML (with images and hyperlinks) using a series of
custom Perl scripts. The MySQL database is part of a gener-
alized metabolomic LIMS system called MetaboLIMS, that
allows data about metabolites, pathways, spectra and concen-
trations to be entered manually. It is a Java application that
uses standard Apache web server technologies such as Java-
server Pages (JSP) and Java servlets to manage web-based
data input and data queries. MetaboLIMS is also designed
to use an imbedded text mining tool called BioSpider (16)
to automatically annotate new metabolite entries (descrip-
tions, physical properties and biological data). MetaboLIMS
and BioSpider, both of which are available on request from
the authors, can be readily used to prepare organism-speciﬁc
metabolome databases similar to the HMDB.
CONCLUSION
In summary, the HMDB is a comprehensive, web-accessible
metabolomics database that brings together quantitative
chemical, physical, clinical and biological data about thou-
sands of endogenous human metabolites. We believe the
HMDB is unique, not only in the type of data it provides
but also in the level of integration and depth of coverage it
achieves. The HMDB is also a work in progress. Just like
GenBank during the 1990s, the HMDB is going through a
rapid phase of growth with constant additions and corrections
being made and the release of different database ‘builds’
every two months. Approximately, 100 new compounds are
being added every month. These updates will continue
throughout most of 2007 after which the HMDB will move
from a strictly curated database model to a public-deposition
model. Overall, it is hoped that the HMDB will serve as a
useful model for future metabolomics databases and that it
will serve members of the metabolomics research community
as well as educators, students, clinicians and the general
public.
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